Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000620 · ClinicalTrials.gov registry record · Phase 3
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
A Phase 3 study of Hypertension and Diabetes Mellitus, Type 2, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 3
- Development phase
- 10,251
- Enrollment target
- 7
- Study locations
NCT00000620: Completed Phase 3 study of Hypertension and Diabetes Mellitus, Type 2, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00000620 is a Phase 3 study of Hypertension and Diabetes Mellitus, Type 2 that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 10,251 participants, above the 3,486-participant average among 470 other Hypertension trials with a reported enrollment target (194% higher). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000620, a Phase 3 study of Hypertension and Diabetes Mellitus, Type 2, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 10,251 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
Primary Outcome
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial). In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm parti
Conditions Studied
Interventions
- DRUG Anti-hyperglycemic Agents
- DRUG Anti-hypertensive Agents
- DRUG Blinded fenofibrate or placebo plus simvastatin
Study Locations (7)
Minnesota
- Minneapolis Medical Research Foundation - Minneapolis
New York
- Columbia University - New York
North Carolina
- Wake Forest University - Winston-Salem
Ohio
- Case Western Reserve University - Cleveland
Tennessee
- Veterans Affairs - Memphis
Washington
- University of Washington - Seattle
Ontario
- McMaster University - Hamilton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,251 participants |
| Start Date | 1999-09 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
What the finished NCT00000620 record still lists
NCT00000620 is an interventional study that assigns participants to a tested intervention. Its 10,251 participants enrollment target places it among the larger protocols in the corpus, above the 3,486-participant average among 470 other Hypertension trials with a reported enrollment target (194% higher).
The record links to 7 conditions, with Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Anti-hyperglycemic Agents is the first listed.
NCT00000620 lists 7 locations in 7 states (Minnesota, New York, North Carolina).
Frequently Asked Questions
What is clinical trial NCT00000620 about?
NCT00000620 is a clinical study titled "Action to Control Cardiovascular Risk in Diabetes (ACCORD)". The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.
What is the current status of trial NCT00000620?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 10,251 participants. The study started on 1999-09. Estimated completion is 2012-12.
What conditions does trial NCT00000620 study?
This clinical trial studies the following conditions: Hypertension, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Diabetes Mellitus, Atherosclerosis.
What interventions are being tested in trial NCT00000620?
The interventions under investigation include: Anti-hyperglycemic Agents (DRUG), Anti-hypertensive Agents (DRUG), Blinded fenofibrate or placebo plus simvastatin (DRUG).
Who is sponsoring clinical trial NCT00000620?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000620 being conducted?
This trial has 7 study locations across Minnesota, New York, North Carolina, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000620's enrollment target sits among peer trials
10,251 21st of 470 higher than 450 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04332783 · 10,120 participants · NA
Isolating and Mitigating Sequentially Dependent Perceptual Errors in Clinical Visual Search
- NCT07157774 · 10,450 participants · Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- NCT05759299 · 10,500 participants
International obServational sTudy on AiRway manaGement in operAting Room and Non-operaTing Room anaEsthesia
- NCT06891222 · 10,500 participants
A Study of Electrocardiogram and Focused Cardiac Ultrasound for Enhanced Cardiac Disease Screening
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia